NL-OMON44667已完成3 期
An extension study to evaluate the sustainability of clinical benefits, safety and tolerability of secukinumab in patients with active Ankylosing Spondylitis (CAIN457F2305E1) - CAIN457F2305E1
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •Subjects must have completed the core study
- •Subjects who are deemed by the investigator to benefit from continued secukinumab therapy
排除标准
- •Any subject taking other concomitant biologic immunomodulating agent(s) except secukinumab during the core study
- •Pregnancy, lactation.
- •Women of childbearing potential who do not use adequate contraception.
研究者
相似试验
进行中(未招募)
1 期
3-year follow-up study of secukinumab treatment in patients with active Ankylosing SpondylitisEUCTR2013-001089-40-NLovartis Pharma Services AG300
进行中(未招募)
1 期
3-year follow-up study of secukinumab treatment in patients with active Ankylosing SpondylitisEUCTR2013-001089-40-BGovartis Pharma Services AG274
进行中(未招募)
1 期
3-year follow-up study of secukinumab treatment in patients with active Ankylosing SpondylitisAnkylosing spondylitisMedDRA version: 19.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-001089-40-GBovartis Pharma Services AG300
进行中(未招募)
1 期
3-year follow-up study of secukinumab treatment in patients with active Ankylosing SpondylitisAnkylosing spondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-001089-40-DEovartis Pharma Services AG274
进行中(未招募)
1 期
3-year follow-up study of secukinumab treatment in patients with active Ankylosing SpondylitisAnkylosing spondylitisMedDRA version: 18.1Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-001089-40-BEovartis Pharma Services AG300
